The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: HSBC Rises After Upbeat Third Quarter

Mon, 29th Oct 2018 10:51

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------HSBC, up 4.7%. The Asia-focused bank reported an "encouraging" third quarter with consensus beating profit. For the three months ended September, pretax profit rose 28% to USD5.92 billion from USD4.62 billion the year prior. Excluding the impact of currency translation, pretax profit rose 16% on the year before. Revenue rose 1.6% to USD13.80 billion from USD13.58 billion the year before. Revenue performance was driven by "strong" growth in all of HSBC's three main global businesses. Shore Capital called HSBC's third-quarter results strong, saying adjusted pretax profit of USD6.19 billion, up 16% on year, was 8% better than consensus at USD5.73 billion and 6% better than Shore's own forecast of USD5.86 billion. Group operating expenses decreased 6.8% to USD7.97 billion from USD8.55 billion the year before. This is largely due the bank's significant items decreasing to USD228 million from USD762 million. The large drop in one-off costs included the non-recurrence of "costs to achieve", which had been USD700 million in the year-ago comparative period. ----------Shire, up 2.5%. Japanese drugmaker Takeda Pharmaceutical said it is considering selling an experimental inflammatory bowel disease drug that is under development by its takeover target Shire. Takeda confirmed its discussion with the European Commission regarding potential overlap between its marketed product Entyvio and Shire's pipeline compound SHP647. SHP647 is a human monoclonal antibody that targets mucosal addressin cell adhesion molecule, which is currently undertaking phase III clinical trials. Takeda has proposed a potential divestment of SHP647 and associated rights. Takeda confirmed on Monday that there are no discussions with the European Commission regarding any other marketed products or assets in the pipeline.----------FTSE 100 - LOSERS----------Just Eat, down 5.2%. Peel Hunt downgraded the online takeaway platform to Sell from Buy. The broker said the rise of rivals Uber and Deliveroo could lead to the demise of Just Eat, given the two can outspend the FTSE 100 constituent and outperform in the smartphone space. Bloomberg in September reported that ride-hailing app Uber - which also offers a food delivery service Uber Eats - was in early discussions with Deliveroo, as part of its strategy to invest and partner with rivals ahead of its planned initial public offering next year.----------OTHER MAIN MARKET AND AIM - WINNERS----------N4 Pharma, up 20%. The cancer-focused pharmaceutical company's shares rose after a key research study demonstrated positive results for its Nuvec delivery system. Since June, N4 Pharma has conducted a research study to determine the level of immune response Nuvec can deliver, using both messenger RNA and plasmid DNA when combined with the antigen Ovalbumin. The results demonstrates that the Nuvec themselves have a clear adjuvant effect to help deliver a level of immune response for both the mRNA and pDNA antigens compared to other delivery systems. As Nuvec will not require an additional adjuvant when formulating a vaccine when used as a delivery system, this could lead to reduced production costs for a final vaccine, as less antigen would be required. In addition, the level of immune response generated by Nuvec particles is within acceptable levels, showing no adverse toxicity.----------Lok'n Store, up 10%. The storage company said its earnings grew in its recently ended financial year following a rise in occupancy and store numbers. Lok'n Store said pretax profit in the year to the end of July improved to GBP5.3 million from GBP4.0 million reported a year earlier, as revenue rose to GBP17.8 million from GBP16.7 million. The company noted the result was driven by occupancy increases in both old and new stores. Tight control over operating costs led to a 2% increase in self-storage margins, which has also contributed in pushing the company's profit to "record level". Lok'nStore declared an annual dividend of 11 pence per share, up 10% from 10p paid the year prior.----------OTHER MAIN MARKET AND AIM - LOSERS----------Warpaint Group, down 43%. The colour cosmetics supplier said the UK market has remained challenging for the company with softening sales, even as it expects a rise in profit and revenue for 2018. Warpaint said its UK market, which accounted for 44% of group's sales in the first half of the year, saw further softening following the end of the interim period due to retailers reducing their stock levels and Christmas orders. The group said the reduction in previously anticipated UK sales will hurt its performance for 2018, which will not be completely offset by an outperformance in its sales territories overseas. As at September 30, sales in the US were up 60% compared to the same period in 2017, and sales in the EU were up 14% year-on-year.----------Gama Aviation, down 17%. The aviation service provider lowered its full-year expectations after trading in some of its divisions has not improved "sufficiently" during the second half of 2018. Gama said it now expects the annual underlying operating profit to be USD3 million below its original expectations. In 2017, Gama generated underlying operating profit of USD18.7 million. On a divisional basis, the company's Air unit saw stable performance in Europe, Middle East & Asia. However, profit from the US is now below Gama's expectations due to slower-than-anticipated growth in charter and aircraft management revenue. In Asia, Gama's associate China Air Services has continued to underperform with the unexpected loss of contracts significantly harming margins. ----------
More News
24 Aug 2018 11:54

LONDON MARKET MIDDAY: Stocks Up; Powell To Make Jackson Hole Debut

LONDON (Alliance News) - Stocks in London were marginally higher at midday on Friday ahead of a highly anticipated speech from the head of the US Federal Reserve.With US-China trade talks demoting a

Read more
24 Aug 2018 10:39

WINNERS & LOSERS SUMMARY: Shire Rises As US FDA Approves Takhzyro Drug

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 2.6%. The Irish pharmaceutical company said a

Read more
24 Aug 2018 08:38

LONDON MARKET OPEN: Stocks Mixed, Shire Rises After Drug Approval

LONDON (Alliance News) - Stock prices in London were mixed early Friday, as markets await US Federal Reserve Chair Jerome Powell's speech in Wyoming later in the day. In the large cap index rose

Read more
24 Aug 2018 08:06

FDA gives nod to Shire's TAKHZYRO treatment

(Sharecast News) - Shire announced on Friday that, following priority review, the US Food and Drug Administration (FDA) has approved the 'TAKHZYRO' (lanadelumab-flyo) injection for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older.

Read more
24 Aug 2018 07:41

LONDON MARKET PRE-OPEN: Slightly Lower Call Ahead Of Powell Speech

LONDON (Alliance News) - Stock prices in London are seen lower on Friday ahead of US Federal Reserve Chair Jerome Powell's speech later during the day, while in a quiet day for UK company news In

Read more
13 Aug 2018 10:31

WINNERS & LOSERS SUMMARY: Chemring Says Fatal Accident To Hurt Profit

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------BAE up 0.8%. a

Read more
13 Aug 2018 09:21

Shire Partner Shionogi Files New Drug Application For Intuniv In Japan

LONDON (Alliance News) - Irish drugmaker Shire PLC said on Monday its Japanese partner Shionogi & Co Ltd has submitted a new drug application for the manufacture and marketing of Intuniv in is

Read more
13 Aug 2018 07:51

Shire and Shionogi apply to expand ADHD treatment to adults

(Sharecast News) - Shire and Shionogi have applied to expand the use in Japan of co-developed drug Intuniv to treat adults for attention deficit hyperactivity disorder.

Read more
31 Jul 2018 12:51

TOP NEWS: Shire Income Up In 2nd-Quarter Ahead Of Takeover By Takeda

LONDON (Alliance News) - Irish biotechnology company Shire PLC on Tuesday posted a more than doubled pretax income in the second quarter, ahead of its upcoming takeover by Takeda Pharmaceutical Co

Read more
31 Jul 2018 12:12

Shire posts 4 pct rise in Q2 earnings ahead of sale to Takeda

LONDON, July 31 (Reuters) - Shire, the London-listed pharmaceutical group being bought by Japan's Takeda, reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to just

Read more
31 Jul 2018 12:08

Shire's quarterly sales rise on immunology demand

(Sharecast News) - Shire reported healthy sales growth in the second quarter as the biotech company pressed ahead with its acquisition by Takeda of Japan.

Read more
31 Jul 2018 08:05

UPDATE 1-Takeda posts weakest Q1 profit in three years

* Q1 operating profit Y98.9 bln vs Y195 bln a year earlier * Takeda booked gains from asset sales a year earlier (Adds details) TOKYO, July 31 (Reuters) - Japan's Takeda Co Ltd a

Read more
25 Jul 2018 07:00

RPT-ANALYSIS-Buy yen in crisis? Not this year

* Yen weakest G10 currency this month despite global turbulence * Investors doubt BOJ can reduce stimulus aggressively * Japanese purchases of foreign equities highest in nearly Bond

Read more
24 Jul 2018 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 25 July GlaxoSmithKlineHalf Year Results (at 1200 BST)Vodafone GroupTrading 26

Read more
24 Jul 2018 15:08

ANALYSIS-Buy yen in crisis? Not this year

* Yen weakest G10 currency this month despite global turbulence * Investors doubt BOJ can reduce stimulus aggressively * Japanese purchases of foreign equities highest in nearly Bond

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.